Novo Nordisk's Wegovy Pill Shows 21.6% Weight Loss in Early Responders, Doubles Mobility Gains
Event summary
- Wegovy pill (oral semaglutide 25 mg) achieved 21.6% weight loss in early responders by week 64 of the OASIS 4 trial.
- Nearly 80% of participants with poor physical function saw clinically meaningful improvements in mobility.
- Indirect treatment comparisons showed Wegovy pill delivered greater weight loss and lower discontinuation rates due to side effects than competitor orforglipron.
- Data presented at the European Congress on Obesity 2026 in Istanbul, Türkiye.
The big picture
Novo Nordisk's latest data reinforces Wegovy pill's efficacy in weight loss and physical function improvements, positioning it as a leading oral obesity treatment. The findings come at a time when the obesity market is expanding, with increasing demand for effective, tolerable, and convenient treatment options. The indirect comparison with orforglipron highlights Wegovy pill's competitive edge in both efficacy and patient retention, which could drive market share gains.
What we're watching
- Regulatory Approval
- Whether the EMA and other regulatory authorities will approve Wegovy pill pending marketing applications.
- Market Differentiation
- How Novo Nordisk will leverage these findings to solidify Wegovy pill's position against competitors like orforglipron.
- Patient Adoption
- The pace at which early responders and mobility improvements will influence patient preference and long-term adherence.
Related topics